Hormone therapy study could unlock kidney disease secrets

NCT ID NCT07542964

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how sex hormones from gender-affirming therapy change kidney function. Researchers will measure kidney performance, blood flow, and insulin sensitivity in 60 transgender people before and after one year of hormone treatment. The goal is to understand why men and women have different rates of kidney disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why men and women have different risks for kidney disease, potentially guiding future treatments.
What could go wrong
This is an early observational study with only 60 participants, so findings may not apply broadly. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC, location VU medical centre, internal medicine

    Amsterdam, North Holland, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.